Posted by Michael Wonder on 03 Dec 2018
Celltrion seeks European approval for Remsima SC
3 December 2018 - South Korean biopharmaceutical firm Celltrion said Monday that it has sought European approval for the sale of its biosimilar drug Remsima SC.
The EMA will review Celltrion's application to sell the subcutaneous (SC) version of Remsima, a biosimilar copy of Janssen Biotech, Inc.'s Remicade, the company said.
Remsima, administered through intravascular injections, is used in the treatment of a number of diseases, from rheumatoid arthritis to Crohn's diseas, Celltrion said. The SC version allows patients to conveniently inject it by themselves, unlike the intravenous formulation that requires patients to visit hospitals.
